CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer
Gastric Cancer · 2026
DOI: 10.1007/s10120-026-01769-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2026. Verfasst von Chao Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. Hauptthemen laut MEDLINE: Chemokine CXCL12, Stomach Neoplasms, Tumor-Associated Macrophages, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department, Beijing Hospitals Authority Youth Programme.
Abstract (Originalsprache)
Objective
Immunotherapy offers promise for gastric cancer (GC) patients, yet its efficacy is substantially limited by high rates of treatment resistance, the mechanisms of which remain incompletely characterised. We aimed to delineate the role and mechanistic basis of CXCL12 in conferring anti-PD-1 resistance in GC.
Methods
An anti-PD-1-resistant GC mouse model was established through chronic anti-PD-1 induction and in vivo tumour tissue passaging. Human and murine GC cell lines stably overexpressing CXCL12 (OE-CXCL12) were generated via lentiviral transduction to construct corresponding OE-CXCL12 GC mouse models. Single-cell transcriptomics analysed the tumour microenvironment (TME) in anti-PD-1-resistant GC. Molecular docking and Drug Affinity Responsive Target Stability (DARTS) assays predicted and validated ligand-receptor binding, respectively. RNA or protein expression of specific molecules was quantified by RT-qPCR, ELISA, immunofluorescence, and western blotting.
Results
Anti-PD-1-resistant GC models showed upregulated CXCL12, PD-L1, and CD206 expression with unchanged PD-1. OE-CXCL12 reduced anti-PD-1 sensitivity, elevated M2-TAM infiltration and TGF-β, IL-10, IL-4 levels in TME, reduced M1-TAM and CD8⁺ T cell infiltration and IL-12 level, with differentially expressed genes enriched in HIF-1, PD-L1/PD-1 checkpoint, and PI3K/AKT signalling pathways. M2-TAM-conditioned medium elevated SOX2, OCT-4, NANOG in GC cells. Mechanistically, CXCL12 binds CXCR4 to activate PI3K/AKT/HIF-1α, promoting PD-L1 expression and M2-TAM polarisation. CXCL12 inhibition recovered anti-PD-1 efficacy.
Conclusions
This identifies CXCL12 as a novel anti-PD-1 resistance gene in GC, with the CXCL12/CXCR4/PI3K/AKT/HIF-1α axis induces anti-PD-1 tolerance through a dual-pathway mechanism of promoting PD-L1 expression and M2-TAM polarisation, providing potential therapeutic strategies to prevent and reverse anti-PD-1 resistance in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
- Beijing Municipal Geriatric Medical Research Center, Beijing, 100053, China.
- School of Pharmacy, Zunyi Medical University, Guizhou, 563006, China.
- Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing, 100141, China.
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. zhanglan@xwhosp.org.
- Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. dongxianzhe@xwhosp.org.
Förderung
- National Natural Science Foundation of China
- Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department
- Beijing Hospitals Authority Youth Programme
- Youth Programme of Xuanwu Hospital of Capital Medical University
- Youth Program of Beijing Municipal TCM Science and Technology Development Fund
Zitieren
APA
Wu, C., Li, B., Li, H., Zhu, P., Wang, Y., Li, X., Feng, Y., Zhang, L., Cheng, Z., Gao, D., Zhang, L., & Dong, X. (2026). CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-026-01769-0
Vancouver
Wu C, Li B, Li H, Zhu P, Wang Y, Li X, et al. CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer. Gastric Cancer. 2026. doi:10.1007/s10120-026-01769-0
BibTeX
@article{Wu2026,
author = {Wu, Chao and Li, Boya and Li, Huiling and Zhu, Panjie and Wang, Yichen and Li, Xiaoxi and Feng, Yingnan and Zhang, Li and Cheng, Zizhao and Gao, Dan and Zhang, Lan and Dong, Xianzhe},
title = {CXCL12 upregulates PD-L1 expression and promotes M2 polarisation of tumour-associated macrophages to confer anti-PD-1 resistance in gastric cancer},
journal = {Gastric Cancer},
year = {2026},
doi = {10.1007/s10120-026-01769-0}
}
EUVIMED